Cosmetic cross-reference

Arginine

CAS 74-79-3

Arginine (CAS 74-79-3) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 184 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

184

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Arginine

CAS Number

74-79-3

UNII

94ZLA3W45F

InChIKey

ODKSFYDXXFIFQN-BYPYZUCNSA-N

ChEMBL ID

CHEMBL1485

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3

Late-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL1485 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 8 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	12142.441176470587 nM	16	-
-	AC50	8837.016 nM	5	-
-	IC50	21665 nM	4	-
-	Kd	24666.666666666668 nM	3	-
-	MIC	2890000 nM	3	-
-	EC50	2.1 ug.mL-1	2	-
Nitric oxide synthase, inducible Enzyme	Kd	5.15	-	Homo sapiens
G-protein coupled receptor family C group 6 member A GPCR	EC50	4.4	-	Homo sapiens

SOURCE DrugCentral 14 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Hyperammonaemic crisis	18	138.837	10073509
Haematuria	41	81.824	10018867
Blindness cortical	11	54.901	10005177
Premature baby	27	51.012	10036590
Hyperammonaemia	17	50.475	10020575
Foetal growth restriction	16	43.432	10070531
Ammonia increased	12	35.397	10001946
Infantile apnoea	8	30.926	10077321
Device related sepsis	10	29.725	10069802
Blood osmolarity decreased	7	28.666	10005696
Selective eating disorder	8	26.306	10078069
Status epilepticus	13	25.165	10041962
Right ventricular failure	12	23.532	10039163
Twin pregnancy	5	20.488	10045188

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
GPRC6 GPRC6A	Full agonist	4.4 pEC50	15576628

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Arginine	1091	SU	MTHSPL
ARGININE	1091	SU	MTHSPL
arginine	1091	SU	MTHSPL
arginine	1091	IN	RXNORM

SOURCE SIDER 57 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Anaphylactic shock	arginine	LLT	C0002792
Anaphylactic shock	arginine	PT	C0002792
Anorexia	arginine	LLT	C0003123
Brain oedema	arginine	PT	C1527311
Choking	arginine	LLT	C0008301
Choking	arginine	PT	C0008301
Decreased appetite	arginine	PT	C0232462
Dermatitis	arginine	PT	C0011603
Edema cerebral	arginine	LLT	C0006114
Extravasation	arginine	LLT	C0015376
Extravasation	arginine	PT	C0015376
Flushing	arginine	LLT	C0016382
Flushing	arginine	PT	C0016382
Haematuria	arginine	LLT	C0018965
Haematuria	arginine	PT	C0018965
Headache	arginine	LLT	C0018681
Headache	arginine	PT	C0018681
Hyperhidrosis	arginine	PT	C0020458
Hypersensitivity	arginine	LLT	C0020517
Hypersensitivity	arginine	PT	C0020517
Hypoaesthesia	arginine	PT	C0020580
Injection site reaction	arginine	LLT	C0151735
Injection site reaction	arginine	PT	C0151735
Lethargy	arginine	LLT	C0023380
Lethargy	arginine	PT	C0023380
Nasal obstruction	arginine	LLT	C0027429
Nasal obstruction	arginine	PT	C0027429
Nausea	arginine	LLT	C0027497
Nausea	arginine	PT	C0027497
Necrosis	arginine	LLT	C0027540
Necrosis	arginine	PT	C0027540
Numbness	arginine	LLT	C0028643
Paraesthesia oral	arginine	PT	C0521591
Perioral tingling	arginine	LLT	C1168149
Phlebitis superficial	arginine	LLT	C0750876
Phlebitis superficial	arginine	PT	C0750876
Platelet count decreased	arginine	LLT	C0392386
Platelet count decreased	arginine	PT	C0392386
Rash	arginine	LLT	C0015230
Rash	arginine	PT	C0015230
Rash macular	arginine	LLT	C0221201
Rash macular	arginine	PT	C0221201
Sensory loss	arginine	PT	C0278134
Sickle cell anaemia	arginine	LLT	C0002895
Sickle cell anaemia	arginine	PT	C0002895
Skin exfoliation	arginine	PT	C0237849
Skin necrosis	arginine	LLT	C0151799
Skin necrosis	arginine	PT	C0151799
Surgery	arginine	PT	C0543467
Surgical intervention	arginine	LLT	C0549433
Sweating	arginine	LLT	C0038990
Swelling	arginine	LLT	C0038999
Swelling	arginine	PT	C0038999
Tachycardia	arginine	LLT	C0039231
Tachycardia	arginine	PT	C0039231
Vomiting	arginine	LLT	C0042963
Vomiting	arginine	PT	C0042963

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Arginine used for in pharmaceutical contexts?

Arginine (CAS 74-79-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Arginine?

Arginine has 184 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hyperammonaemic crisis, Haematuria, Blindness cortical, Premature baby, Hyperammonaemia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Arginine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Arginine with EU status "permitted".

What clinical phase is Arginine in?

Arginine is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Arginine?

Arginine has 8 bioactivity rows in this page query. Rendered target entries include Nitric oxide synthase, inducible, G-protein coupled receptor family C group 6 member A.